Alterity Therapeutics Ltd Stock Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 84.04M 72.58M 68.2M 62.03M 117M 8.04B 119M 799M 312M 4.02B 316M 309M 13.37B | P/E 2026 * |
-0.42x | P/E 2027 * | -0.42x |
|---|---|---|---|---|---|
| Enterprise Value | 38.78M 33.5M 31.48M 28.63M 53.82M 3.71B 54.71M 369M 144M 1.86B 146M 142M 6.17B | EV / Sales 2026 * |
14.1x | EV / Sales 2027 * | 20.6x |
| Free-Float |
91.94% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 2021-01-06 |
Abby Macnish
DFI | Director of Finance/CFO | - | 2024-09-29 |
| Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 2005-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 2011-08-07 |
David Stamler
BRD | Director/Board Member | 65 | 2025-11-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 84.04M | |
| -1.78% | -1.68% | +1.99% | +13.84% | 48.42B | |
| +0.85% | -0.70% | +465.55% | +579.03% | 43.66B | |
| -2.40% | -0.23% | +12.20% | +70.22% | 39.51B | |
| -2.01% | -0.85% | +24.95% | +7.51% | 38.95B | |
| -0.50% | +0.85% | +20.60% | +49.65% | 32.61B | |
| -0.59% | -2.06% | +26.13% | +117.79% | 16.15B | |
| +0.38% | -3.23% | - | - | 16.32B | |
| +0.49% | +0.92% | +4.32% | +22.16% | 14.16B | |
| -0.43% | +4.70% | +79.75% | +29.11% | 13.37B | |
| Average | -0.39% | +0.49% | +79.44% | +111.17% | 29.24B | |
| Weighted average by Cap. | -0.91% | +0.59% | +97.63% | +134.68% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 2.74M 2.37M 2.23M 2.03M 3.81M 262M 3.87M 26.1M 10.21M 131M 10.31M 10.08M 437M | 2.09M 1.81M 1.7M 1.54M 2.9M 200M 2.95M 19.88M 7.77M 100M 7.85M 7.68M 333M |
| Net income | -14.76M -12.75M -11.98M -10.9M -20.49M -1.41B -20.83M -140M -54.89M -707M -55.43M -54.23M -2.35B | -29.99M -25.9M -24.34M -22.14M -41.62M -2.87B -42.3M -285M -112M -1.44B -113M -110M -4.77B |
| Net Debt | -45.25M -39.08M -36.73M -33.4M -62.8M -4.33B -63.83M -430M -168M -2.17B -170M -166M -7.2B | -40.9M -35.33M -33.2M -30.19M -56.76M -3.91B -57.7M -389M -152M -1.96B -154M -150M -6.51B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
